These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10340907)

  • 1. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
    Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
    Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
    Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
    Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
    Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
    APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
    Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
    J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
    Pappot H; Høyer-Hansen G; Rønne E; Hansen HH; Brünner N; Danø K; Grøndahl-Hansen J
    Eur J Cancer; 1997 May; 33(6):867-72. PubMed ID: 9291807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
    Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J
    Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
    Eugen-Olsen J; Gustafson P; Sidenius N; Fischer TK; Parner J; Aaby P; Gomes VF; Lisse I
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):686-92. PubMed ID: 12150480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.